Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 60,195

Document Document Title
WO/2018/012845A1
The present application relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.  
WO/2018/011186A1
The present invention relates to metal complexes and electronic devices, in particular organic electroluminescent devices containing said metal complexes.  
WO/2018/012573A1
The present invention provides a method for producing a high-purity crystal of a uracil compound by employing an operation that can be carried out on an industrial scale. More specifically, the present invention provides a method for pro...  
WO/2018/010345A1
The present invention discloses a 5-HT1F receptor agonist, 2,4,6-trifluoro-N-[6-[(1-methyl-piperidin-4-yl)carbonyl]pyri din-2-yl]-benzamide (lasmiditan), and a chloride salt crystalline form thereof. When compared to a solid form of lasm...  
WO/2018/011681A1
Compounds, pharmaceutically acceptable salts thereof, are disclosed wherein the compounds have the structure of (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, a...  
WO/2018/013789A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2018/013867A1
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and ...  
WO/2018/010514A1
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the heterocyclic compound, a preparation method therefor, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The comp...  
WO/2018/013482A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N oxides, and salts thereof, wherein A, X1, X2, X3 and R2 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Form...  
WO/2018/011227A1
The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...  
WO/2018/013676A1
Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions,...  
WO/2018/013840A1
Methods of editing a target genomic region(s), methods of repairing of a DNA break via a HDR pathway, methods of inhibiting or suppressing repair of a DNA break via a NHEJ pathway, and methods of modifying expression of a gene(s) or prot...  
WO/2018/011376A1
A subject of the present invention is a compound having the general formula (I) a pharmaceutically acceptable salt thereof or a tautomeric form thereof, wherein A, B3, B4, B5, Y, X, B1 and B2 are as defined in any one of claims 1 to 10. ...  
WO/2018/011090A1
The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations w...  
WO/2018/013689A1
Provided herein are solid dispersions comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a polymer and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione and a coformer. Pharmaceutical ...  
WO/2018/009501A1
2-Substituted-4-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl )pentanamido)butanoic acids are disclosed. These compounds selectively inhibit αVβ3 without activating the αVβ3 receptor. They are useful for treating osteoporosis, acute m...  
WO/2018/009505A1
The present disclosure generally relates to compounds of formula (I), wherin R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use....  
WO/2018/006795A1
Disclosed are an aromatic acetylene or aromatic ethylene compound, an intermediate, a preparation method, a pharmaceutical composition and a use thereof. The aromatic acetylene or aromatic ethylene compound has a significant inhibitory e...  
WO/2018/009622A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2018/009625A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/009717A1
Stable, clear, ophthalmic formulations and methods of use for an opthalmologically therapeutic effective amount of a TRPAl antagonist, the formulation comprising buffer system, a viscosity enhancing agent, optionally a preservative, with...  
WO/2018/009678A1
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I), wherein R1, R2a, R,2b, Z, X and Y are ...  
WO/2018/009007A1
The present application provides: a heterocyclic compound capable of greatly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light emitting device; and an organic light emitting device h...  
WO/2018/009009A1
The present application provides a heterocyclic compound capable of remarkably improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device, and an organic light-emitting device...  
WO/2018/008897A1
The present invention relates to a latex bead composite having a novel 4-(4-methylpiperazinyl)styrylpyridine derivative multiply coupled therewith, a target material detecting kit including the same as an active ingredient, and a detecti...  
WO/2018/008727A1
The present invention provides a heterocyclic compound that exhibits a superior control against harmful arthropods and that is represented by formula (I): (I) [in the formula, Q1 represents an oxygen atom or the like; Q2 represents an ox...  
WO/2018/002847A1
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, aza-substituted triterpenoid compounds that possess unique antiviral activity are provided as HIV matu...  
WO/2018/006074A2
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2018/005713A1
The new piperazine derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities such as lysosome storage diseases, muscular dystrophy, age-related common neurodegenerative diseases, oxidative stres...  
WO/2018/003924A1
Provided is a novel pest control agent, especially a bactericide or a nematicide. An alkynylpyridine-substituted amide compound represented by formula (I) or a salt thereof; and a pest control agent which contains the compound or the sal...  
WO/2018/005192A1
Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing...  
WO/2018/001973A1
The present invention relates to pyrazole derivatives of formula (I) having pharmacological activity towards the α2δ subunit, in particular the α2δ-1 subunit, of the voltage-gated calcium channel, in particular having dual pharmacolo...  
WO/2018/004290A1
The present invention relates to a novel substituted pyrazole derivative, having the effect of inhibiting the serine/threonine kinase activity, targeting the receptor ALK5 of TGF-β. A pharmaceutical composition containing a compound of ...  
WO/2018/001948A1
The present invention relates to compounds of formula (I): (I) or pharmaceutically acceptable salts thereof, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.  
WO/2018/002220A1
The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A- II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no mo...  
WO/2018/004306A1
The present invention relates to a pyrazolopyrirmidine derivative, or a pharmaceutically acceptable salt thereof. The compound according to the present invention can be usefully used for the prevention or treatment of diseases which are ...  
WO/2018/002848A1
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibito...  
WO/2018/005591A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...  
WO/2018/005552A1
Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.  
WO/2018/005435A1
The invention relates to 4,6-diaminoquinazoline derivatives of formula I which are modulators of the Cot (cancer Osaka thyroid) kinase, also known as MAP3K8, EST or Tlp-2, and their use for treating e.g. cancer, diabetes and inflammatory...  
WO/2018/005418A1
Solid state forms of Neratinib and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.  
WO/2018/005177A1
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these co...  
WO/2018/002941A1
Novel processes of preparing block polyester copolymers while precisely controlling the stereoconfiguration (e.g., tacticity), chemical composition and/or length of each unit (block) are provided. Block polyester copolymers featuring des...  
WO/2017/223016A1
The present invention provides compounds of Formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA rec...  
WO/2017/223452A1
The present application provides bifunctional compounds of Formula (I): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation ...  
WO/2017/219953A1
A pomalidomide crystallization technology. The crystallization technology comprises: mixing pomalidomide with mixed solvent A for dissolution, and concentrating an obtained clear solution to obtain pomalidomide crystals. The used crystal...  
WO/2017/219087A1
The present invention relates to new multi-functional compounds that are useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease, to the preparation of the compounds, and to compositions including the compounds...  
WO/2017/223514A1
In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as...  
WO/2017/223516A1
The application relates to phthalazine derivatives of formula (I) which are inhibitors of PARP1, PARP2 and/or tubulin and thus useful for the treatment of cancer. Also disclosed are pharmaceutical formulations containing such compounds, ...  
WO/2017/221008A1
The invention relates to compounds of general formula (I): wherein R1, R2, R3, R10 and X- are as defined herein. The compounds are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respirat...  

Matches 1 - 50 out of 60,195